Opexa Therapeutics has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained full compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement. The letter noted that as of December 31, 2012, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the company has regained compliance with NASDAQ Marketplace Rule 5550(a)(2) and NASDAQ considers the matter closed. The company has submitted its plan to regain compliance with NASDAQ’s minimum stockholders’ equity listing standard set forth in listing rule 5550(b)(1), and NASDAQ is currently reviewing the plan. If the company’s plan is accepted, NASDAQ may grant an extension until May 25, 2013 for the company to regain compliance with the minimum stockholders’ equity standard.